Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J. Overman, Thierry André, Andrew Hill et al.|The Lancet Oncology|2017Cited by 2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal CancerMichael J. Overman, Thierry André, Sara Lonardi et al.|Journal of Clinical Oncology|2018Cited by 2.1k
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene AlterationWassim Abida, Akash Patnaik, David Campbell et al.|Journal of Clinical Oncology|2020Cited by 676
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142Thierry André, Michael J. Overman, Sara Lonardi et al.|Annals of Oncology|2022Cited by 253